Two antibody-based therapeutics targeting components of this signaling complex have been approved recently; a monoclonal antibody directed against the IL-6 receptor, tociluzimab, approved for the treatment of CD, RA and juvenile idiopathic arthritis [7], and a monoclonal antibody (mAb) specific for IL-6, siltuximab, approved for the treatment of CD [8]. The gene discussed is IL6; the disease is rheumatoid arthritis.